STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
10 janv. 2024 03h30 HE
|
Alvotech
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatologyAuthorization paves...
Alvotech og STADA hljóta markaðsleyfi fyrir fyrstu líftæknilyfjahliðstæðuna við Stelara í Evrópu
10 janv. 2024 03h30 HE
|
Alvotech
Markaðsleyfi er veitt á Evrópska efnahagssvæðinu fyrir hliðstæðu við Stelara, líftæknilyf sem notað er til meðferðar við meltingar-, húð- og gigtarsjúkdómum Samkeppni um ustekinumab markaðinn í...
STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
10 janv. 2024 03h30 HE
|
Alvotech
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatology Authorization paves...
Niðurstaða rannsóknar á sjúklingum sýnir sömu klínísku virkni AVT06 líftæknilyfjahliðstæðu Alvotech og Eylea
03 janv. 2024 03h30 HE
|
Alvotech
Aðalendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT06 og Eylea (aflibercept) í sjúklingum með aldurstengda vota augnbotnahrörnun (AMD) ...
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
03 janv. 2024 03h30 HE
|
Alvotech
The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular...
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
11 déc. 2023 08h00 HE
|
AiViva Biopharma
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
29 nov. 2023 04h00 HE
|
Alvotech
REYKJAVIK, Iceland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech kynnir jákvæðar niðurstöður úr rannsókn á lyfjahvörfum AVT05, fyrirhugaðri líftæknilyfjahliðstæðu við Simponi® og Simponi Aria®
29 nov. 2023 04h00 HE
|
Alvotech
Aðalendapunktar rannsóknarinnar voru uppfylltir, en henni var ætlað að bera saman lyfjahvörf, öryggi og þolanleika AVT05 og Simponi í heilbrigðum einstaklingum. Alvotech (NASDAQ: ALVO) kynnti í dag...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
29 nov. 2023 04h00 HE
|
Alvotech
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint Alvotech (NASDAQ: ALVO), a global biotech...
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
28 nov. 2023 16h15 HE
|
Alvotech
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the...